GlassScriptPhysician profile
Michal S Wall
NPI 1871701706
$2,953.59
in general payments reported to CMS, 2019-2025
20 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $220 · 2021: $364 · 2022: $747 · 2023: $680 · 2024: $133 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $620.61 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $610.37 | 2019-2023 | Farxiga |
| Abbvie INC. | $330.75 | 2023-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $292.18 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $285.87 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Kvk-Tech, INC. | $161.07 | 2019 | |
| Penumbra, INC. | $141.35 | 2021 | |
| Pfizer INC. | $102.58 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $101.47 | 2021 | |
| Sanofi Pasteur INC. | $44.24 | 2019-2020 | |
| Lundbeck LLC | $41.89 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $34.77 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $31.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.49 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $29.10 | 2025 | |
| Boston Scientific Corporation | $19.37 | 2023 | Bodyguardian |
| Amgen INC. | $17.70 | 2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $15.00 | 2022 | |
| Dexcom, INC. | $13.82 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michal Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.